Dennis S. Charney

Dennis S. Charney's AcademicInfluence.com Rankings

Dennis S. Charney

Medical

#59

World Rank

#102

Historical Rank

#31

USA Rank

Pharmacology

#19

World Rank

#25

Historical Rank

#11

USA Rank

medical Degrees

Dennis S. Charney

Philosophy

#1640

World Rank

#2940

Historical Rank

#645

USA Rank

Logic

#289

World Rank

#587

Historical Rank

#124

USA Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Why Is Dennis S. Charney Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Dennis S. Charney is an American biological psychiatrist and researcher, with expertise in the neurobiology and treatment of mood and anxiety disorders. He is the author of Neurobiology of Mental Illness, The Physician's Guide to Depression and Bipolar Disorders and Molecular Biology for the Clinician, as well as the author of over 600 original papers and chapters. In 2022, he was listed #52 on Research.com's "Top Medicine Scientists in the United States," with an h-index of 194 with 146,109 citations across 651 publications. Charney is known for demonstrating that ketamine is effective for treating depression. Ketamine's use as a rapidly-acting anti-depressant is recognized as a breakthrough treatment in mental illness.

(See a Problem?)

Dennis S. Charney's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. (1989) (6725)
The development of a Clinician-Administered PTSD Scale (1995) (4671)
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. (1994) (3177)
Antidepressant effects of ketamine in depressed patients (2000) (2977)
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. (2006) (2920)
The Yale-Brown Obsessive Compulsive Scale. II. Validity. (1989) (2580)
Hippocampal volume reduction in major depression. (2000) (1643)
MRI-based measurement of hippocampal volume in patients with combat-related posttraumatic stress disorder. (1995) (1448)
Psychobiological mechanisms of resilience and vulnerability: implications for successful adaptation to extreme stress. (2004) (1434)
Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. (1996) (1271)
Magnetic resonance imaging-based measurement of hippocampal volume in posttraumatic stress disorder related to childhood physical and sexual abuse—a preliminary report (1997) (1196)
A CLINICIAN RATING SCALE FOR ASSESSING CURRENT AND LIFETIME PTSD: THE CAPS-1 (1990) (1187)
The cellular neurobiology of depression (2001) (1142)
Discovering the neural basis of human social anxiety: a diagnostic and therapeutic imperative. (2004) (1141)
Psychobiology and molecular genetics of resilience (2009) (1127)
Discovering Endophenotypes for Major Depression (2004) (1091)
Mood Disorders in the Medically Ill: Scientific Review and Recommendations (2005) (1009)
The psychobiology of depression and resilience to stress: implications for prevention and treatment. (2005) (1007)
Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. (1990) (964)
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. (2013) (926)
Neurobiology of resilience (2011) (913)
Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. (1998) (805)
Childhood trauma associated with smaller hippocampal volume in women with major depression. (2002) (789)
Neural correlates of exposure to traumatic pictures and sound in Vietnam combat veterans with and without posttraumatic stress disorder: a positron emission tomography study (1999) (719)
Neuropsychopharmacology : The Fifth Generation of Progress (2002) (703)
Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder. (1997) (690)
MRI and PET study of deficits in hippocampal structure and function in women with childhood sexual abuse and posttraumatic stress disorder. (2003) (683)
Neural correlates of memories of childhood sexual abuse in women with and without posttraumatic stress disorder. (1999) (673)
Defining clinical phenotypes of juvenile mania. (2003) (653)
Measurement of Dissociative States with the Clinician-Administered Dissociative States Scale (CADSS) (1998) (647)
Receptor sensitivity and the mechanism of action of antidepressant treatment. Implications for the etiology and therapy of depression. (1981) (643)
Rapid and Longer-Term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-Resistant Major Depression (2013) (626)
Social support and resilience to stress: from neurobiology to clinical practice. (2007) (616)
Psychobiologic mechanisms of posttraumatic stress disorder. (1993) (605)
The Science of Resilience: Implications for the Prevention and Treatment of Depression (2012) (603)
Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression (2010) (587)
Childhood physical abuse and combat-related posttraumatic stress disorder in Vietnam veterans. (1993) (575)
Noradrenergic function in panic anxiety. Effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. (1984) (558)
Noradrenergic mechanisms in stress and anxiety: I. preclinical studies (1996) (558)
Reduced Cortical γ-Aminobutyric Acid Levels in Depressed Patients Determined by Proton Magnetic Resonance Spectroscopy (1999) (551)
Abnormal noradrenergic function in posttraumatic stress disorder. (1993) (549)
Effects of Intravenous Ketamine on Explicit and Implicit Measures of Suicidality in Treatment-Resistant Depression (2009) (547)
Chronic PTSD in Vietnam combat veterans: course of illness and substance abuse. (1996) (536)
Role of norepinephrine in the pathophysiology and treatment of posttraumatic stress disorder (1999) (528)
Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments (2002) (517)
Effects of early adverse experiences on brain structure and function: clinical implications (2000) (514)
Reduced brain serotonin transporter availability in major depression as measured by [123I]-2β-carbomethoxy-3β-(4-iodophenyl)tropane and single photon emission computed tomography (1998) (512)
Reduced volume of orbitofrontal cortex in major depression (2002) (507)
Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for Difficult-to-Treat depression (2003) (503)
Enhanced suppression of cortisol following dexamethasone administration in posttraumatic stress disorder. (1993) (494)
Adolescent immaturity in attention-related brain engagement to emotional facial expressions (2003) (493)
Decreased single‐photon emission computed tomographic {123I}β‐CIT striatal uptake correlates with symptom severity in parkinson's disease (1995) (487)
Hippocampal volume, memory, and cortisol status in major depressive disorder: effects of treatment (2004) (476)
A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. (1997) (475)
A functional magnetic resonance imaging study of bipolar disorder: state- and trait-related dysfunction in ventral prefrontal cortices. (2003) (465)
Deficits in short-term memory in posttraumatic stress disorder. (1993) (464)
Long-term treatment with paroxetine increases verbal declarative memory and hippocampal volume in posttraumatic stress disorder (2003) (464)
Depression and Bipolar Support Alliance consensus statement on the unmet needs in diagnosis and treatment of mood disorders in late life. (2003) (455)
Ventrolateral prefrontal cortex activation and attentional bias in response to angry faces in adolescents with generalized anxiety disorder. (2006) (452)
Neurobiology of Mental Illness (2004) (452)
Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. (2006) (437)
Decreased benzodiazepine receptor binding in prefrontal cortex in combat-related posttraumatic stress disorder. (2000) (436)
Comorbidity of mood and anxiety disorders (2000) (428)
Consistency of memory for combat-related traumatic events in veterans of Operation Desert Storm. (1997) (427)
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. (2014) (419)
Neurobiological mechanisms in major depressive disorder (2009) (417)
Abnormal attention modulation of fear circuit function in pediatric generalized anxiety disorder. (2007) (412)
Life Stress, Genes, and Depression: Multiple Pathways Lead to Increased Risk and New Opportunities for Intervention (2004) (408)
Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. (2000) (402)
Attention bias to threat in maltreated children: implications for vulnerability to stress-related psychopathology. (2005) (401)
Understanding resilience (2013) (399)
Increased anxiogenic effects of caffeine in panic disorders. (1985) (394)
Dissociation and posttraumatic stress disorder in Vietnam combat veterans. (1992) (382)
Amygdala and hippocampal volumes in adolescents and adults with bipolar disorder. (2003) (378)
Choice selection and reward anticipation: an fMRI study (2004) (375)
A Randomized Controlled Trial of Intranasal Ketamine in Major Depressive Disorder (2014) (375)
The symptoms of major depressive illness. (1981) (365)
SPECT imaging of dopamine and serotonin transporters with [123I]β‐CIT: Pharmacological characterization of brain uptake in nonhuman primates (1993) (363)
Alterations of benzodiazepine receptors in type II alcoholic subjects measured with SPECT and [123I]iomazenil. (1998) (358)
Ketamine for Depression: Where Do We Go from Here? (2012) (357)
Reduced Serotonin Type 1A Receptor Binding in Panic Disorder (2004) (356)
The revised monoamine theory of depression: a modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans. (1996) (354)
Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo. (1989) (354)
A double-blind, placebo-controlled study of memantine in the treatment of major depression. (2006) (347)
Spect imaging of striatal dopamine release after amphetamine challenge in humans: Relationship between subjective effects and dopamine release (1995) (347)
Positron emission tomographic imaging of neural correlates of a fear acquisition and extinction paradigm in women with childhood sexual-abuse-related post-traumatic stress disorder (2004) (347)
Yohimbine induced anxiety and increased noradrenergic function in humans: effects of diazepam and clonidine. (1983) (341)
Monoamine dysfunction and the pathophysiology and treatment of depression. (1998) (339)
[sup 123 I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease (1996) (337)
Startle gating deficits occur across prepulse intensities in schizophrenic patients (1992) (329)
Deficits in short-term memory in adult survivors of childhood abuse (1995) (316)
An open-label trial of riluzole in patients with treatment-resistant major depression. (2004) (316)
Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action (1999) (315)
Serotonin and the neurobiology of depression. Effects of tryptophan depletion in drug-free depressed patients. (1994) (314)
Evidence for continuing neuropsychological impairments in depression. (2004) (314)
Pramipexole for bipolar II depression: a placebo-controlled proof of concept study (2004) (305)
Noradrenergic and serotonergic function in posttraumatic stress disorder. (1997) (303)
VNS Therapy in Treatment-Resistant Depression: Clinical Evidence and Putative Neurobiological Mechanisms (2006) (302)
Noradrenergic mechanisms in stress and anxiety: II. Clinical studies. (1996) (300)
EFFECTS OF KETAMINE ON EXPLICIT AND IMPLICIT SUICIDAL COGNITION: A RANDOMIZED CONTROLLED TRIAL IN TREATMENT‐RESISTANT DEPRESSION (2014) (298)
Graphical, Kinetic, and Equilibrium Analyses of in vivo [123I]β-CIT Binding to Dopamine Transporters in Healthy Human Subjects (1994) (296)
Major depression in patients with agoraphobia and panic disorder. (1984) (295)
Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. (1990) (293)
Transcranial magnetic stimulation and auditory hallucinations in schizophrenia (2000) (290)
A randomized clinical trial of repetitive transcranial magnetic stimulation in the treatment of major depression (2000) (286)
Neural correlates of declarative memory for emotionally valenced words in women with posttraumatic stress disorder related to early childhood sexual abuse (2003) (285)
Psychobiological mechanisms of resilience: Relevance to prevention and treatment of stress-related psychopathology (2007) (285)
Cortisol response to a cognitive stress challenge in posttraumatic stress disorder (PTSD) related to childhood abuse (2003) (284)
Neurobiological mechanisms of panic anxiety: biochemical and behavioral correlates of yohimbine-induced panic attacks. (1987) (282)
Plasma neuropeptide-Y concentrations in humans exposed to military survival training (2000) (280)
Neural correlates of the classic color and emotional stroop in women with abuse-related posttraumatic stress disorder (2004) (280)
Serotonergic function in depression. Prolactin response to intravenous tryptophan in depressed patients and healthy subjects. (1984) (278)
Cognitive dysfunction in depression: Neurocircuitry and new therapeutic strategies (2011) (275)
Clinician-Administered PTSD Scale (2011) (275)
Imaging D2 Receptor Occupancy by Endogenous Dopamine in Humans (1997) (275)
Positron emission tomography measurement of cerebral metabolic correlates of yohimbine administration in combat-related posttraumatic stress disorder. (1997) (275)
Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. (1999) (275)
Agoraphobia with panic attacks. Development, diagnostic stability, and course of illness. (1986) (273)
Relationships among plasma dehydroepiandrosterone sulfate and cortisol levels, symptoms of dissociation, and objective performance in humans exposed to acute stress. (2004) (273)
Reduced hippocampal volume in unmedicated, remitted patients with major depression versus control subjects (2005) (273)
Microdialysis and SPECT measurements of amphetamine‐induced dopamine release in nonhuman primates (1997) (272)
Abnormal regulation of noradrenergic function in panic disorders. Effects of clonidine in healthy subjects and patients with agoraphobia and panic disorder. (1986) (271)
Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. (2010) (271)
Response to emotional expressions in generalized social phobia and generalized anxiety disorder: evidence for separate disorders. (2008) (268)
Neural and behavioral responses to tryptophan depletion in unmedicated patients with remitted major depressive disorder and controls. (2004) (266)
Positron emission tomography measurement of cerebral metabolic correlates of tryptophan depletion-induced depressive relapse. (1997) (266)
Neuroanatomical circuits modulating fear and anxiety behaviors (2003) (265)
Developing an Agenda for Translational Studies of Resilience and Vulnerability Following Trauma Exposure (2006) (264)
Mechanisms of action of atypical antipsychotic drugs Implications for novel therapeutic strategies for schizophrenia (1991) (261)
A functional neuroanatomy of anxiety and fear: implications for the pathophysiology and treatment of anxiety disorders. (1996) (260)
The FKBP5-Gene in Depression and Treatment Response—an Association Study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort (2008) (255)
Are child-, adolescent-, and adult-onset depression one and the same disorder? (2001) (254)
Serotonergic and noradrenergic dysregulation in alcoholism: m-chlorophenylpiperazine and yohimbine effects in recently detoxified alcoholics and healthy comparison subjects. (1996) (246)
Lithium carbonate augmentation of antidepressant treatment. An effective prescription for treatment-refractory depression. (1983) (245)
NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. (1999) (245)
Frontotemporal alterations in pediatric bipolar disorder: results of a voxel-based morphometry study. (2005) (245)
Hereditary Factors in Sleepwalking and Night Terrors (1980) (240)
The diagnostic validity of anxiety disorders and their relationship to depressive illness. (1985) (239)
A developmental examination of gender differences in brain engagement during evaluation of threat (2004) (239)
Functional neuroanatomical correlates of the effects of stress on memory (1995) (239)
Carbon dioxide-induced anxiety. Behavioral, physiologic, and biochemical effects of carbon dioxide in patients with panic disorders and healthy subjects. (1988) (238)
An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression (2005) (238)
Neurobiological and clinical consequences of stress : from normal adaptation to post-traumatic stress disorder (1995) (236)
Decreased Cerebrospinal Fluid Allopregnanolone Levels in Women with Posttraumatic Stress Disorder (2006) (236)
Trauma, resilience, and recovery in a high-risk African-American population. (2008) (235)
Adrenergic receptor sensitivity in depression. Effects of clonidine in depressed patients and healthy subjects. (1982) (235)
Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects. (1988) (235)
Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder. (1990) (235)
Effects of early stress on brain structure and function: Implications for understanding the relationship between child maltreatment and depression (2001) (233)
Reductions in occipital cortex GABA levels in panic disorder detected with 1h-magnetic resonance spectroscopy. (2001) (232)
[123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane: high-affinity SPECT radiotracer of monoamine reuptake sites in brain. (1991) (231)
Fear-potentiated startle in posttraumatic stress disorder (1995) (228)
Interactive effects of subanesthetic ketamine and haloperidol in healthy humans (1999) (228)
Amino Acid Neurotransmitters Assessed by Proton Magnetic Resonance Spectroscopy: Relationship to Treatment Resistance in Major Depressive Disorder (2009) (227)
Low baseline and yohimbine-stimulated plasma neuropeptide Y (NPY) levels in combat-related PTSD (2000) (226)
Elevated Serotonin Transporter Binding in Major Depressive Disorder Assessed Using Positron Emission Tomography and [11C]DASB; Comparison with Bipolar Disorder (2007) (224)
Social support and resilience to stress across the life span: A neurobiologic framework (2008) (224)
Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial (2015) (222)
Frontostriatal abnormalities in adolescents with bipolar disorder: preliminary observations from functional MRI. (2003) (222)
Baseline startle amplitude and prepulse inhibition in Vietnam veterans with posttraumatic stress disorder (1996) (221)
Transcranial magnetic stimulation of left temporoparietal cortex in three patients reporting hallucinated “voices” (1999) (219)
New insights into the role of cortisol and the glucocorticoid receptor in severe depression (2002) (219)
Age-Related Decline in Striatal Dopamine Transporter Binding with Iodine-123-β-CITSPECT (1995) (219)
A Functional Magnetic Resonance Imaging Study of Deliberate Emotion Regulation in Resilience and Posttraumatic Stress Disorder (2009) (218)
How does social support enhance resilience in the trauma-exposed individual? (2015) (217)
Rapid serotonin depletion as a provocative challenge test for patients with major depression: relevance to antidepressant action and the neurobiology of depression. (1991) (216)
Ketamine Treatment and Global Brain Connectivity in Major Depression (2017) (215)
The role of serotonin in the pathophysiology and treatment of schizophrenia. (1997) (212)
Ketamine: A Paradigm Shift for Depression Research and Treatment (2019) (210)
Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. (2007) (208)
Hormone profiles in humans experiencing military survival training (2000) (206)
Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression. (1996) (203)
Attending to the Emotional Well-Being of the Health Care Workforce in a New York City Health System During the COVID-19 Pandemic (2020) (203)
Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. (2007) (202)
Trauma exposure, posttraumatic stress disorder and depression in an African-American primary care population. (2006) (202)
Deficits in social cognition and response flexibility in pediatric bipolar disorder. (2005) (201)
Enduring Mental Health Morbidity and Social Function Impairment in World Trade Center Rescue, Recovery, and Cleanup Workers: The Psychological Dimension of an Environmental Health Disaster (2008) (199)
Mood-congruent bias in affective go/no-go performance of unmedicated patients with major depressive disorder. (2005) (198)
Neural response to catecholamine depletion in unmedicated subjects with major depressive disorder in remission and healthy subjects. (2008) (196)
Brain SPECT imaging of amphetamine-induced dopamine release in euthymic bipolar disorder patients. (2000) (195)
Relationship Among Plasma Cortisol, Catecholamines, Neuropeptide Y, and Human Performance During Exposure to Uncontrollable Stress (2001) (193)
Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression. (2014) (192)
Personality traits and disorder in depression. (1981) (191)
Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients. (1993) (189)
Brain derived neurotrophic factor (BDNF) gene variants and Alzheimer's disease, affective disorders, posttraumatic stress disorder, schizophrenia, and substance dependence (2006) (189)
Regulation of Cellular Plasticity Cascades in the Pathophysiology and Treatment of Mood Disorders (2003) (188)
Delusional and nondelusional unipolar depression: further evidence for distinct subtypes. (1981) (188)
Exaggerated acoustic startle reflex in Gulf War veterans with posttraumatic stress disorder. (1996) (187)
Neurotransmitter alterations in PTSD: catecholamines and serotonin. (1999) (187)
Recognition of facial emotions among maltreated children with high rates of post-traumatic stress disorder. (2008) (187)
Why are some individuals more resilient than others: the role of social support (2016) (187)
Deficits in hippocampal and anterior cingulate functioning during verbal declarative memory encoding in midlife major depression. (2004) (187)
Yale-Brown Obsessive Compulsive Scale (Y-BOCS) (1991) (186)
Selective reduction in amygdala volume in pediatric anxiety disorders: A voxel-based morphometry investigation (2005) (186)
Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. (1997) (185)
Dissociation of ketamine effects on rule acquisition and rule implementation: possible relevance to NMDA receptor contributions to executive cognitive functions (2000) (184)
Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans (1998) (184)
The relationship between panic disorder and major depression. A new family study. (1993) (183)
Increased pituitary and adrenal reactivity in premenopausal women with posttraumatic stress disorder (2001) (183)
Mood disorders and medical illness: a major public health problem (2003) (181)
Monoamines and the mechanism of antidepressant action: effects of catecholamine depletion on mood of patients treated with antidepressants. (1993) (179)
Serotonin Transporter Binding in Bipolar Disorder Assessed using [11C]DASB and Positron Emission Tomography (2006) (179)
Life-threatening danger and suppression of attention bias to threat. (2010) (177)
Carbon dioxide sensitivity in panic anxiety. Ventilatory and anxiogenic response to carbon dioxide in healthy subjects and patients with panic anxiety before and after alprazolam treatment. (1986) (177)
Serotonin function in anxiety (1987) (176)
Situational panic attacks. Behavioral, physiologic, and biochemical characterization. (1987) (175)
Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. (2007) (173)
SPECT [I-123]iomazenil measurement of the benzodiazepine receptor in panic disorder (2000) (173)
Psychosocial facets of resilience: implications for preventing posttrauma psychopathology, treating trauma survivors, and enhancing community resilience (2014) (173)
Clinical phenomenology and neurobiology of cocaine abstinence: a prospective inpatient study. (1991) (172)
Neurobiology of anxiety disorders and implications for treatment. (2006) (172)
Neurobiological mechanisms in human anxiety evidence supporting central noradrenergic hyperactivity (1983) (171)
Ketamine safety and tolerability in clinical trials for treatment-resistant depression. (2015) (171)
Recent advances in the neurobiology of anxiety disorders: Implications for novel therapeutics (2008) (170)
A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy. (1991) (168)
Effects of rapid tryptophan depletion in patients with seasonal affective disorder in remission after light therapy. (1996) (168)
Differential effects of 5-HTTLPR genotypes on the behavioral and neural responses to tryptophan depletion in patients with major depression and controls. (2006) (167)
A functional neuropeptide Y Leu7Pro polymorphism associated with alcohol dependence in a large population sample from the United States. (2002) (166)
Nightmares: clinical characteristics and personality patterns. (1980) (165)
Novel Drugs and Therapeutic Targets for Severe Mood Disorders (2008) (164)
Amphetamine‐stimulated dopamine release competes in vivo for [123I]IBZM binding to the D2 receptor in nonhuman primates (1992) (164)
Psychobiological Mechanisms of Resilience and Vulnerability (2004) (161)
Attention bias variability and symptoms of posttraumatic stress disorder. (2014) (160)
The psychobiological basis of posttraumatic stress disorder. (1996) (159)
SPECT measurement of benzodiazepine receptors in human brain with iodine-123-iomazenil: kinetic and equilibrium paradigms. (1994) (158)
Coping and PTSD symptoms in Pakistani earthquake survivors: purpose in life, religious coping and social support. (2013) (156)
Age, Rapid-Cycling, and Pharmacotherapy Effects on Ventral Prefrontal Cortex in Bipolar Disorder: A Cross-Sectional Study (2006) (156)
Dose-related ethanol-like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics. (1998) (152)
Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists (2010) (151)
Yale Brown Obsessive Compulsive Scale (2017) (151)
The serotonin hypothesis of obsessive compulsive disorder: implications of pharmacologic challenge studies. (1992) (150)
Drug treatment of panic disorder: the comparative efficacy of imipramine, alprazolam, and trazodone. (1986) (149)
Habenula Volume in Bipolar Disorder and Major Depressive Disorder: A High-Resolution Magnetic Resonance Imaging Study (2011) (149)
Preliminary evidence of low cortical GABA levels in localized 1H-MR spectra of alcohol-dependent and hepatic encephalopathy patients. (1999) (147)
Serotonin function and mechanism of action of antidepressant treatment. Effects of amitriptyline and desipramine. (1984) (146)
Central functions of neuropeptide Y in mood and anxiety disorders (2011) (144)
Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. (2007) (144)
Noradrenergic neuronal dysregulation in panic disorder: the effects of intravenous yohimbine and clonidine in panic disorder patients (1992) (144)
Posttraumatic Growth in Former Vietnam Prisoners of War (2008) (143)
Neuroscience research agenda to guide development of a pathophysiologically based classification system. (2002) (143)
Irritability in Pediatric Mania and Other Childhood Psychopathology (2003) (143)
Use of the Structured Clinical Interview for DSM-IV Dissociative Disorders for systematic assessment of dissociative symptoms in posttraumatic stress disorder. (1993) (143)
Understanding resilience: New approaches for preventing and treating PTSD (2016) (142)
Iodine-123-β-CIT and Iodine-123-FPCIT SPECT Measurement of Dopamine Transporters in Healthy Subjects and Parkinson's Patients (1998) (142)
Increased Amygdala Activity During Successful Memory Encoding in Adolescent Major Depressive Disorder: An fMRI Study (2006) (141)
Single photon emission computed tomography imaging of monoamine reuptake sites in primate brain with [123I]CIT. (1991) (141)
Psychogenic Lowering of Urinary Cortisol Levels Linked to Increased Emotional Numbing and a Shame-Depressive Syndrome in Combat-Related Posttraumatic Stress Disorder (2001) (140)
Reduced posterior hippocampal volume in posttraumatic stress disorder. (2008) (140)
[123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. (1996) (137)
An Increased Capacity for Adrenal DHEA Release is Associated with Decreased Avoidance and Negative Mood Symptoms in Women with PTSD (2004) (137)
Resilience in the Third Year of Medical School: A Prospective Study of the Associations Between Stressful Events Occurring During Clinical Rotations and Student Well-Being (2009) (137)
The clinical use of clonidine in abrupt withdrawal from methadone. Effects on blood pressure and specific signs and symptoms. (1981) (136)
Glutamate and post-traumatic stress disorder: toward a psychobiology of dissociation. (1999) (136)
Neuroendocrine and behavioral effects of dietary tryptophan restriction in healthy subjects. (1989) (136)
Smaller head of the hippocampus in Gulf War-related posttraumatic stress disorder (2005) (135)
Presynaptic adrenergic receptor sensitivity in depression. The effect of long-term desipramine treatment. (1981) (134)
Night terrors. Clinical characteristics and personality patterns. (1980) (134)
Early coadministration of clonazepam with sertraline for panic disorder. (2001) (133)
Preliminary evidence of an association between sensorimotor gating and distractibility in psychosis. (1996) (133)
Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds. (2014) (133)
Tryptophan depletion in patients with obsessive-compulsive disorder who respond to serotonin reuptake inhibitors. (1994) (132)
Noradrenergic function and the mechanism of action of antianxiety treatment. II. The effect of long-term imipramine treatment. (1985) (132)
Priority actions to improve the care of persons with co-occurring substance abuse and other mental disorders: A call to action (2004) (131)
SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of beta-CIT. (1996) (130)
Resilience and mental health : challenges across the lifespan (2011) (130)
Resilience: The Science of Mastering Life's Greatest Challenges (2012) (130)
Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome (2017) (129)
Regional brain metabolic correlates of alpha-methylparatyrosine-induced depressive symptoms: implications for the neural circuitry of depression. (2003) (128)
Temporal lobe volume in panic disorder — a quantitative magnetic resonance imaging study (2000) (127)
Serotonin Function and Human Anxiety Disorders a (1990) (126)
Clonidine in outpatient detoxification from methadone maintenance. (1985) (124)
Variability of response to lithium augmentation in refractory depression. (1986) (124)
Research on major depression: strategies and priorities. (2003) (124)
Lithium carbonate augmentation of antidepressant treatment (1984) (123)
Norepinephrine dysfunction in depression. (2000) (122)
Neurobiology of Post-Traumatic Stress Disorder (1995) (121)
Researching the pathophysiology of pediatric bipolar disorder (2003) (121)
Trauma-related symptoms in veterans of Operation Desert Storm: a 2-year follow-up. (1995) (121)
Normal Prefrontal Gamma-Aminobutyric Acid Levels in Remitted Depressed Subjects Determined by Proton Magnetic Resonance Spectroscopy (2005) (120)
Assessment of α2 adrenergic autoreceptor function in humans: Effects of oral yohimbine (1982) (120)
Toward an integrated neurobiology of panic disorder. (1997) (117)
Outcome of intensive inpatient treatment for combat-related posttraumatic stress disorder. (1996) (117)
SOCIAL SUPPORT AND RESILIENCE TO STRESS (2007) (116)
Quality of life in schizophrenia: a comparison of instruments. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. (2000) (115)
Screening and Management of Depression in Patients With Cardiovascular Disease: JACC State-of-the-Art Review. (2019) (115)
Transient depressive relapse induced by catecholamine depletion: potential phenotypic vulnerability marker? (1999) (115)
Open Prospective Trial of Fluoxetine for Posttraumatic Stress Disorder (1993) (114)
Neurocognitive Effects of Ketamine and Association with Antidepressant Response in Individuals with Treatment-Resistant Depression: A Randomized Controlled Trial (2015) (114)
Depression and bipolar support alliance consensus statement on the unmet needs in diagnosis and treatment of mood disorders in children and adolescents. (2003) (114)
Abrupt Discontinuation of Tricyclic Antidepressant Drugs: Evidence for Noradrenergic Hyperactivity (1982) (114)
Psychiatric disorders in relatives of probands with panic disorder and/or major depression. (1994) (113)
National Depressive and Manic-Depressive Association consensus statement on the use of placebo in clinical trials of mood disorders. (2002) (112)
Reduced global functional connectivity of the medial prefrontal cortex in major depressive disorder (2016) (112)
The Neurobiological Basis of Anxiety and Fear: Circuits, Mechanisms, and Neurochemical Interactions (Part II) (1998) (111)
Effects of the beta-blocker propranolol on cued and contextual fear conditioning in humans (2004) (109)
IV glycine and oral d-cycloserine effects on plasma and CSF amino acids in healthy humans (2000) (109)
The combined use of clonidine and naltrexone as a rapid, safe, and effective treatment of abrupt withdrawal from methadone. (1986) (109)
Clinical and medication outcome after short-term alprazolam and behavioral group treatment in panic disorder. 2.5 year naturalistic follow-up study. (1989) (109)
Attention to threats and combat-related posttraumatic stress symptoms: prospective associations and moderation by the serotonin transporter gene. (2013) (109)
Adaptive and maladaptive psychobiological responses to severe psychological stress: implications for the discovery of novel pharmacotherapy (2004) (107)
Acute tryptophan depletion (1992) (106)
Sex Differences in Diencephalon Serotonin Transporter Availability in Major Depression (2006) (105)
Treatment of severe obsessive-compulsive disorder with fluvoxamine. (1987) (105)
Attention bias away from threat during life threatening danger predicts PTSD symptoms at one‐year follow‐up (2011) (105)
SPECT Quantification of [123I]Iomazenil Binding to Benzodiazepine Receptors in Nonhuman Primates: II. Equilibrium Analysis of Constant Infusion Experiments and Correlation with in vitro Parameters (1994) (105)
Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients. (1997) (104)
Anger and anxiety responses to m-chlorophenylpiperazine in generalized anxiety disorder (1992) (104)
Sustained Low-Grade Pro-inflammatory State in Unmedicated, Remitted Women with Major Depressive Disorder as Evidenced by Elevated Serum Levels of the Acute Phase Proteins C-reactive Protein and Serum Amyloid A (2007) (104)
No association between D2 dopamine receptor (DRD2) “A” system alleles, or DRD2 haplotypes, and posttraumatic stress disorder (1999) (103)
Significance of Adolescent Neurodevelopment for the Neural Circuitry of Bipolar Disorder (2004) (103)
Emerging drugs for the treatment of anxiety (2015) (102)
Amygdala volume in depressed patients with bipolar disorder assessed using high resolution 3T MRI: The impact of medication (2010) (102)
Somnambulism. Clinical characteristics and personality patterns. (1980) (102)
Genetic polymorphism at the CLOCK gene locus and major depression. (2000) (101)
Effects of ritanserin on the behavioral, neuroendocrine, and cardiovascular responses to meta-chlorophenylpiperazine in healthy human subjects (1991) (101)
RETRACTED: Assessment of the Hypothalamic-Pituitary-Adrenal Axis over a 24-Hour Diurnal Period and in Response to Neuroendocrine Challenges in Women with and without Childhood Sexual Abuse and Posttraumatic Stress Disorder (2003) (100)
Cardiac implications of increased arterial entry and reversible 24-h central and peripheral norepinephrine levels in melancholia. (2005) (99)
An overview of posttraumatic stress disorder in African Americans. (2006) (98)
Trauma-related symptoms in veterans of Operation Desert Storm: a preliminary report. (1993) (98)
Yohimbine-induced withdrawal and anxiety symptoms in opioid-dependent patients (2002) (97)
Clonidine and naltrexone. A safe, effective, and rapid treatment of abrupt withdrawal from methadone therapy. (1982) (96)
Neural mechanisms in dissociative amnesia for childhood abuse: relevance to the current controversy surrounding the "false memory syndrome". (1996) (96)
Compartmental modeling of iodine-123-iodobenzofuran binding to dopamine D2 receptors in healthy subjects. (1994) (96)
Specificity of ethanollike effects elicited by serotonergic and noradrenergic mechanisms. (1994) (94)
Clinical Characteristics of Hospitalized Covid-19 Patients in New York City (2020) (93)
Tryptophan depletion and attenuation of cue-induced craving for cocaine. (1995) (93)
Psychobiologic research in post-traumatic stress disorder. (1994) (93)
m-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients. Evidence implicating serotonergic systems in the positive symptoms of schizophrenia. (1993) (93)
The Biology of Human Resilience: Opportunities for Enhancing Resilience Across the Life Span (2019) (93)
Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol. (2000) (93)
Neurobiology of generalized anxiety disorder. (2001) (91)
The effects of caffeine on plasma MHPG, subjective anxiety, autonomic symptoms and blood pressure in healthy humans. (1984) (91)
Evidence of acoustic startle hyperreflexia in recently detoxified early onset male alcoholics: modulation by yohimbine and m-Chlorophenylpiperazine (mCPP) (1997) (91)
Association between level of emotional intelligence and severity of anxiety in generalized social phobia. (2008) (91)
Effects of a α2C-Adrenoreceptor Gene Polymorphism on Neural Responses to Facial Expressions in Depression (2006) (91)
Risk Factors for the Development of Psychopathology Following Trauma (2015) (89)
Sympathoneural and adrenomedullary functional effects of &agr;2C-adrenoreceptor gene polymorphism in healthy humans (2005) (89)
SPECT Quantification of [123I]Iomazenil Binding to Benzodiazepine Receptors in Nonhuman Primates: I. Kinetic Modeling of Single Bolus Experiments (1994) (89)
Clinical data on the role of serotonin in the mechanism(s) of action of antidepressant drugs. (1990) (88)
Marked Lability in Urinary Cortisol Levels in Subgroups of Combat Veterans With Posttraumatic Stress Disorder During an Intensive Exposure Treatment Program (2002) (87)
Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response (2014) (87)
Alpha 2-adrenergic receptor function in depression. The cortisol response to yohimbine. (1986) (87)
Behavioral, biochemical, and cardiovascular responses to the benzodiazepine receptor antagonist flumazenil in panic disorder (1991) (86)
Emotion recognition deficits in pediatric anxiety disorders: implications for amygdala research. (2005) (85)
Cost-effectiveness of clozapine in patients with high and low levels of hospital use. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. (1999) (85)
Serotonin-specific drugs for anxiety and depressive disorders. (1990) (85)
Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients. (1998) (84)
Altered NMDA Glutamate Receptor Antagonist Response in Recovering Ethanol-Dependent Patients (2003) (83)
Sustained Elevation of Serum Interleukin-6 and Relative Insensitivity to Hydrocortisone Differentiates Posttraumatic Stress Disorder with and Without Depression (2010) (83)
The Case for Shifting Borderline Personality Disorder to Axis I (2008) (83)
Battlefield-like stress following simulated combat and suppression of attention bias to threat (2010) (83)
Relationships between hormonal profile and novelty seeking in combat-related posttraumatic stress disorder (1997) (83)
Serotonin function and depression: neuroendocrine and mood responses to intravenous L-tryptophan in depressed patients and healthy comparison subjects. (1991) (82)
Dr. Southwick and Colleagues Reply (1997) (82)
Biased emotional attention in post-traumatic stress disorder: a help as well as a hindrance? (2007) (82)
Cognitive control of attention is differentially affected in trauma-exposed individuals with and without post-traumatic stress disorder (2012) (81)
Serotonin function in panic disorders. The effect of intravenous tryptophan in healthy subjects and patients with panic disorder before and during alprazolam treatment. (1986) (81)
Effects of desipramine and fluvoxamine treatment on the prolactin response to tryptophan. Serotonergic function and the mechanism of antidepressant action. (1989) (81)
Effects of glucocorticoids on declarative memory function in major depression (2004) (81)
Machine Learning to Predict Mortality and Critical Events in a Cohort of Patients With COVID-19 in New York City: Model Development and Validation (2020) (81)
Lack of behavioral effects of monoamine depletion in healthy subjects (1997) (80)
Lithium treatment and serotoninergic function. Neuroendocrine and behavioral responses to intravenous tryptophan in affective disorder. (1989) (79)
Reward circuitry in resilience to severe trauma: An fMRI investigation of resilient special forces soldiers (2009) (79)
Alpha-2 Adrenergic Receptor Sensitivity and the Mechanism of Action of Antidepressant Therapy (1983) (79)
m-Chlorophenylpiperazine in patients with obsessive-compulsive disorder: Absence of symptom exacerbation (1995) (78)
The use of pindolol with fluoxetine in the treatment of major depression: final results from a double-blind, placebo-controlled trial (1999) (78)
A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder. (2021) (78)
Effects of Cocaine on Hospital Course in Schizophrenia (1993) (78)
Addition of the α2-Antagonist Yohimbine to Fluoxetine: Effects on Rate of Antidepressant Response (2004) (78)
Noradrenergic function in generalized anxiety disorder: Effects of yohimbine in healthy subjects and patients with generalized anxiety disorder (1989) (77)
Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors (2004) (77)
Regulation of neural responses to emotion perception by ketamine in individuals with treatment-resistant major depressive disorder (2015) (77)
Response to meta-chlorophenylpiperazine in panic disorder patients and healthy subjects: Influence of reduction in intravenous dosage (1994) (77)
Impaired presynaptic regulation of norepinephrine in schizophrenia. Effects of clonidine in schizophrenic patients and normal controls. (1982) (77)
Therapeutic Implications of the Hyperglutamatergic Effects of NMDA Antagonists (1999) (75)
Reproducibility of iodine-123-beta-CIT SPECT brain measurement of dopamine transporters. (1996) (74)
Mental health of workers and volunteers responding to events of 9/11: review of the literature. (2008) (74)
Does participation in psychosocial treatment augment the benefit of clozapine? Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. (1998) (74)
Evaluation of the monoamine uptake site ligand [131I]methyl 3β-(4-Iodophenyl)-tropane-2β-carboxylate ([123I]β-CIT) in non-human primates: Pharmacokinetics, biodistribution and SPECT brain imaging coregistered with MRI (1993) (74)
Earthquake impact in a remote South Asian population: psychosocial factors and posttraumatic symptoms. (2010) (74)
Serotonin polymorphisms and posttraumatic stress disorder in a trauma exposed African American population (2009) (74)
No change in serotonin type 1A receptor binding in patients with posttraumatic stress disorder. (2005) (73)
Mentors Enhance Resilience in At-Risk Children and Adolescents (2007) (73)
Animal Models of Relevance to PTSD (1997) (73)
YOHIMBINE ALTERS REGIONAL CEREBRAL BLOOD FLOW IN PANIC DISORDER (1988) (73)
Somnambulistic-like Episodes Secondary to Combined Lithium-Neuroleptic Treatment (1979) (72)
COGNITIVE‐EMOTIONAL TRAINING AS AN INTERVENTION FOR MAJOR DEPRESSIVE DISORDER (2014) (72)
Lithium and serotonin function: implications for the serotonin hypothesis of depression (2005) (72)
Primary affective disorder criteria and the endogenous-reactive distinction. (1980) (72)
Impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. (1999) (71)
Three cases of manic symptoms following yohimbine administration. (1984) (71)
Desipramine-yohimbine combination treatment of refractory depression. Implications for the beta-adrenergic receptor hypothesis of antidepressant action. (1986) (71)
Efficacy of lithium-tranylcypromine treatment in refractory depression. (1985) (71)
Gender differences in cognitive and neural correlates of remembrance of emotional words. (2001) (71)
Corticotropin-releasing factor, interleukin-6, brain-derived neurotrophic factor, insulin-like growth factor-1, and substance P in the cerebrospinal fluid of civilians with posttraumatic stress disorder before and after treatment with paroxetine. (2011) (70)
Cell atrophy and loss in major depression. (1999) (69)
Characterization of radioactive metabolites of 5-HT2A receptor PET ligand [18F]altanserin in human and rodent. (1999) (69)
Characteristics of panic attack subtypes: assessment of spontaneous panic, situational panic, sleep panic, and limited symptom attacks. (1991) (68)
The use of tryptophan depletion to evaluate central serotonin function in depression and other neuropsychiatric disorders (1993) (68)
Is There Anything Really Novel on the Antidepressant Horizon? (2012) (68)
Fluvoxamine/Pimozide Treatment of Concurrent Tourette's and Obsessive-Compulsive Disorder (1990) (67)
Noradrenergic function and the cortisol response to dexamethasone in depression (1985) (67)
The impact of the homecoming reception on the development of posttraumatic stress disorder. The West Haven Homecoming Stress Scale (WHHSS). (1997) (66)
Frontotemporal neural systems in bipolar disorder. (2002) (66)
The neurobiology of posttraumatic stress disorder: An integration of animal and human research. (1999) (66)
Noradrenergic Alterations in Posttraumatic Stress Disorder (1997) (65)
Effects of tryptophan depletion in panic disorder (1994) (65)
Assessment of the hypothalamic-pituitary-adrenal axis over a 24-hour diurnal period and in response to neuroendocrine challenges in women with and without childhood sexual abuse and posttraumatic stress disorder. (2003) (64)
Effects of fluoxetine administration on mood response to tryptophan depletion in healthy subjects (1997) (64)
Monoamine receptor systems and anxiety disorders. (1988) (64)
Seizures induced by abrupt discontinuation of alprazolam. (1984) (64)
Reproducibility of SPECT measurement of benzodiazepine receptors in human brain with iodine-123-iomazenil. (1995) (63)
How long to wait for a response to clozapine: a comparison of time course of response to clozapine and conventional antipsychotic medication in refractory schizophrenia. (1999) (63)
Detecting improvement in quality of life and symptomatology in schizophrenia. (2001) (63)
Memory and learning in pediatric bipolar disorder. (2005) (63)
Age-related decline in striatal dopamine transporter binding with iodine-123-beta-CITSPECT. (1995) (63)
Efficacy of fluvoxamine in treatment-refractory depression. (1988) (63)
Benzodiazepine treatment of panic disorder: a comparison of alprazolam and lorazepam. (1989) (61)
Glycine Site Agonists of the NMDA Receptor: A Review (1995) (61)
Cortisol and DHEA-S are associated with startle potentiation during aversive conditioning in humans (2006) (61)
Effects of sleep deprivation on serotonin function in depression (1994) (61)
Use of neuropsychological assessment in posttraumatic stress disorder (1991) (60)
Cerebral benzodiazepine receptors in depressed patients measured with [123i]iomazenil SPECT (2003) (60)
Reward Processing After Catecholamine Depletion in Unmedicated, Remitted Subjects with Major Depressive Disorder (2009) (60)
Opiate dependence and withdrawal: preliminary assessment using single photon emission computerized tomography (SPECT). (1995) (60)
Yohimbine — facilitated acoustic startle reflex in humans (2005) (60)
Effects of α-Methyl-Para-Tyrosine (AMPT) in Drug-Free Depressed Patients (1996) (60)
Yohimbine use in a natural setting: effects on posttraumatic stress disorder (1999) (60)
Serotonin function in aggression: The effect of acute plasma tryptophan depletion in aggressive patients (1994) (60)
Effects of tryptophan depletion on serum levels of brain-derived neurotrophic factor in unmedicated patients with remitted depression and healthy subjects. (2005) (60)
Opioid antagonist challenges in buprenorphine maintained patients. (1990) (59)
VNS Therapy in Treatment-Resistant Depression: Clinical Evidence and Putative Neurobiological Mechanisms (2006) (59)
Methyl 3β‐(4‐[125I]Iodophenyl)Tropane‐2β‐Carboxylate In Vitro Binding to Dopamine and Serotonin Transporters Under “Physiological” Conditions (1994) (59)
Neurobiology of mental illness, 2nd ed. (2004) (58)
Differential performance on tasks of affective processing and decision-making in patients with Panic Disorder and Panic Disorder with comorbid Major Depressive Disorder. (2006) (58)
Use of Physiological Data From a Wearable Device to Identify SARS-CoV-2 Infection and Symptoms and Predict COVID-19 Diagnosis: Observational Study (2021) (58)
Machine Learning to Predict Mortality and Critical Events in COVID-19 Positive New York City Patients: A Cohort Study. (2020) (58)
Effect of catecholamine depletion on lithium-induced long-term remission of bipolar disorder (1999) (58)
Treatment‐refractory depression: Definitions and characteristics (1997) (58)
No Evidence of Altered In Vivo Benzodiazepine Receptor Binding in Schizophrenia (1999) (57)
Hippocampal N-Acetylaspartate Concentration and Response to Riluzole in Generalized Anxiety Disorder (2008) (57)
The role of the locus coeruleus in the generation of pathological anxiety (2020) (57)
Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial. (2004) (57)
Psychological Impact of the COVID-19 Pandemic on Frontline Health Care Workers During the Pandemic Surge in New York City (2021) (57)
Mazindol treatment for cocaine dependence. (1995) (56)
α2Adrenergic and Opiate Receptor Blockade: Synergistic Effects on Anxiety in Healthy Subjects (1986) (56)
Naltrexone precipitated opiate withdrawal in methadone addicted human subjects: evidence for noradrenergic hyperactivity. (1984) (56)
Neuropeptide Y, resilience, and PTSD therapeutics (2017) (55)
Publication bias and the efficacy of antidepressants. (2009) (55)
Novel Drugs and Therapeutic Targets for Severe Mood Disorders (2008) (54)
Neuroendocrine and behavioral responses to intravenous m-chlorophenylpiperazine (mCPP) in depressed patients and healthy comparison subjects. (1994) (54)
Acute tryptophan depletion: a method of studying antidepressant action. (1992) (53)
Monoamine depletion in unmedicated depressed subjects (2002) (53)
Noradrenergic function in panic disorder. (1990) (52)
Cerebrospinal fluid corticotropin-releasing hormone in healthy humans: effects of yohimbine and naloxone. (2000) (52)
Low early morning plasma cortisol in posttraumatic stress disorder is associated with co-morbid depression but not with enhanced glucocorticoid feedback inhibition (2010) (51)
Plasma MHPG in depression: Effects of acute and chronic desipramine treatment (1981) (51)
Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. (1998) (51)
Ketamine normalizes subgenual cingulate cortex hyper-activity in depression (2020) (50)
After lithium augmentation: a retrospective follow-up of patients with antidepressant-refractory depression. (1990) (50)
Kinetic and equilibrium analyses of [123I]epidepride binding to striatal and extrastriatal dopamine D2 receptors (1999) (50)
Effects of tryptophan depletion on responses to yohimbine in healthy human subjects (1995) (49)
A Randomized Dose-Ranging Study of Neuropeptide Y in Patients with Posttraumatic Stress Disorder (2017) (49)
Failure of chronic antidepressant treatment to alter growth hormone response to clonidine (1982) (49)
Glucocorticoid receptor gene polymorphisms in premenopausal women with major depression. (2008) (49)
PET quantification of 5-HT2A receptors in the human brain: a constant infusion paradigm with [18F]altanserin. (2000) (49)
Yohimbine facilitated acoustic startle in combat veterans with post-traumatic stress disorder (1995) (48)
Alterations in Stress Reactivity After Long‐Term Treatment with Paroxetine in Women with Posttraumatic Stress Disorder (2006) (48)
Changes of benzodiazepine receptors during chronic benzodiazepine administration in humans. (1999) (48)
Regional brain uptake and pharmacokinetics of [123I]N-ω -fluoroalkyl-2β-carboxy-3β-(4-iodophenyl) nortropane esters in baboons (1995) (47)
Moral distress in frontline healthcare workers in the initial epicenter of the COVID‐19 pandemic in the United States: Relationship to PTSD symptoms, burnout, and psychosocial functioning (2021) (47)
Imaging serotonergic neurotransmission in depression: hippocampal pathophysiology may mirror global brain alterations (2000) (47)
An open trial of fluoxetine in the treatment of posttraumatic stress disorder. (1991) (46)
[123I]Iomazenil SPECT benzodiazepine receptor imaging in schizophrenia (1999) (46)
A selective neurokinin-1 receptor antagonist in chronic PTSD: A randomized, double-blind, placebo-controlled, proof-of-concept trial (2011) (45)
Evaluation of the DSM-III criteria for melancholia. (1981) (45)
Effects of dexamethasone on declarative memory function in posttraumatic stress disorder (2004) (44)
Brain catecholamine metabolites and behavior in morphine withdrawal. (1982) (44)
Hospitalised COVID-19 patients of the Mount Sinai Health System: a retrospective observational study using the electronic medical records (2020) (44)
Therapeutic applications and mechanisms of action of monoamine oxidase inhibitor and heterocyclic antidepressant drugs. (1985) (43)
Differential 3H-imipramine platelet binding in patients with panic disorder and depression (1987) (43)
Effects of yohimbine and hydrocortisone on panic symptoms, autonomic responses, and attention to threat in healthy adults (2009) (43)
The effect of neuroleptic discontinuation on psychopathology, involuntary movements, and biochemical measures in patients with persistent tardive dyskinesia (1989) (43)
Hydrocortisone Impairs Hippocampal-Dependent Trace Eyeblink Conditioning in Post-Traumatic Stress Disorder (2006) (43)
The concept of the second generation program in the treatment of post-traumatic stress disorder among vietnam veterans (1994) (43)
A case of sustained remission following an acute course of ketamine in treatment-resistant depression. (2011) (43)
[123I]Iomazenil spect imaging demonstrates significant benzodiazepine receptor reserve in human and nonhuman primate brain (1993) (43)
Effects of the benzodiazepine antagonist flumazenil in PTSD (1995) (42)
Effects of tranylcypromine treatment on neuroendocrine, behavioral, and autonomic responses to tryptophan in depressed patients. (1985) (41)
The biological basis of panic disorder. (1996) (40)
Lithium prevents adaptation of brain dopamine systems to haloperidol in schizophrenic patients (1983) (40)
Computer‐Assisted Coregistration of Multislice SPECT and MR Brain Images by Fixed External Fiducials (1993) (40)
β-Endorphin/β-Lipotropin Immunoreactivity in Endogenous Depression: Effect of Dexamethasone (1986) (40)
Naltrexone augmentation of neuroleptics in schizophrenia. (1998) (39)
Dynamic SPECT imaging after injection of the benzodiazepine receptor ligand [123I]iomazenil in healthy human subjects (1992) (39)
Tryptophan Depletion and Emotional Processing in Healthy Volunteers at High Risk for Depression (2011) (38)
alpha 2-Adrenergic receptor sensitivity in depression. The plasma MHPG, behavioral, and cardiovascular responses to yohimbine. (1988) (38)
Association of Optimism With Cardiovascular Events and All-Cause Mortality: Systematic Review and Meta-Analysis. (2022) (38)
Noradrenergic function and the mechanism of action of antianxiety treatment. I. The effect of long-term alprazolam treatment. (1985) (38)
Neurobiological Mechanisms of Human Anxiety (1990) (38)
The Effect of Mianserin on Alpha-2 Adrenergic Receptor Function in Depressed Patients (1984) (38)
Ineffectiveness of clonidine in the treatment of the benzodiazepine withdrawal syndrome: report of three cases. (1986) (37)
The Neurobiology of Eating Disorders (2013) (37)
Effects of the serotonin reuptake inhibitor fluvoxamine on yohimbine-induced anxiety in panic disorder (1993) (37)
Effects of alpha-methyl-para-tyrosine (AMPT) in drug-free depressed patients. (1996) (37)
In vivo quantification of dopamine D2 receptor parameters in nonhuman primates with [123I]iodobenzofuran and single photon emission computerized tomography. (1994) (37)
Graphical analysis and simplified quantification of striatal and extrastriatal dopamine D2 receptor binding with [123I]epidepride SPECT. (1999) (37)
Experience-dependent plasticity for attention to threat: Behavioral and neurophysiological evidence in humans (2004) (37)
Cracking the moody brain: Lifting the mood with ketamine (2010) (36)
SPECT imaging of the benzodiazepine receptor in non-human primate brain with [123I]Ro 16-0154. (1991) (36)
Preclinical evaluation of [123I]R93274 as a SPECT radiotracer for imaging 5-HT2A receptors. (1997) (36)
Human biodistribution and dosimetry of the SPECT benzodiazepine receptor radioligand iodine-123-iomazenil. (1994) (36)
Noradrenergic response to acute ethanol administration in heathly subjects: comparison with intravenous yohimbine (1995) (36)
Methadone patients exhibit increased startle and cortisol response after intravenous yohimbine (2001) (35)
Single photon emission tomography measurement of benzodiazepine receptor number and affinity in primate brain: a constant infusion paradigm with [123I]iomazenil. (1993) (35)
Resilience in the age of COVID-19 (2021) (35)
NOTCH4 gene haplotype is associated with schizophrenia in African Americans (2004) (35)
Clinical studies of 5-HT function using I.V. l-Tryptophan (1990) (35)
Plasma Neuropeptide Y (NPY) Increases in Humans in Response to the α2 Antagonist Yohimbine (1998) (34)
63 NEUROBIOLOGICAL BASIS OF ANXIETY DISORDERS (2002) (34)
No association between D3 dopamine receptor (DRD3) alleles and cocaine dependence (1996) (34)
Dextromethorphan/quinidine pharmacotherapy in patients with treatment resistant depression: A proof of concept clinical trial. (2017) (34)
Etiological factors in the development of posttraumatic stress disorder. (1995) (34)
Machine Learning to Predict Mortality and Critical Events in COVID-19 Positive New York City Patients (2020) (34)
Development and Reliability of a Method for Using Magnetic Resonance Imaging for the Definition of Regions of Interest for Positron Emission Tomography. (1998) (33)
A neuroimaging method for the study of threat in adolescents. (2003) (33)
Resilience and Personality Traits among Living Liver and Kidney Donors (2014) (33)
Neurobiological correlates of child abuse. (1999) (33)
A Consensus Meeting on Effective Research Practice in PTSD (1998) (32)
Noradrenergic function in schizophrenia. (1987) (32)
Noradrenergic dysregulation in panic disorder (1990) (32)
Acute delivery of attention bias modification training (ABMT) moderates the association between combat exposure and posttraumatic symptoms: A feasibility study (2017) (32)
Long-term outcome of panic disorder after short-term imipramine and behavioral group treatment: 2.9-year naturalistic follow-up study. (1993) (32)
Post Traumatic Stress Disorder: Psychobiological mechanisms of traumatic remembrance. (1995) (32)
Habenula volume in post-traumatic stress disorder measured with high-resolution MRI (2011) (30)
Reduced post-synaptic serotonin type 1A receptor binding in bipolar depression (2013) (30)
Noradrenergic mechanisms in stress and anxiety: II. Clinical studies (1996) (30)
Symptom provocation studies in psychiatric disorders: scientific value, risks, and future (1999) (30)
Response to Zhang et al., (2005) Loss-of-Function Mutation in Tryptophan Hydroxylase-2 Identified in Unipolar Major Depression. Neuron 45, 11–16 (2005) (30)
Tryptophan-deficient diet and amino acid drink deplete plasma tryptophan and induce a relapse of depression in susceptible patients (1992) (30)
Serotonin versus catecholamine deficiency: behavioral and neural effects of experimental depletion in remitted depression (2015) (30)
The revised monoamine theory of depression (1996) (29)
Lithium continuation therapy following ketamine in patients with treatment resistant unipolar depression: a randomized controlled trial (2019) (29)
The efficacies of clozapine and haloperidol in refractory schizophrenia are related to DTNBP1 variation (2009) (29)
Controlled trial of alprazolam supplementation during imipramine treatment of panic disorder. (1992) (29)
Effects of antidepressant treatment on neural correlates of emotional and neutral declarative verbal memory in depression. (2007) (29)
An Integrated Approach to Evaluate Faculty Members’ Research Performance (2009) (28)
Intravenous diazepam fails to change growth hormone and cortisol secretion in humans (1986) (28)
Test-retest reproducibility of extrastriatal dopamine D2 receptor imaging with [123I]epidepride SPECT in humans. (2000) (27)
The effect of intravenous L-tryptophan on prolactin and growth hormone and mood in healthy subjects (2004) (27)
Noradrenergic and serotonergic receptor system function in panic disorder and depression (1988) (27)
Clinical and psychopharmacologic factors influencing family burden in refractory schizophrenia. The Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. (2000) (27)
Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression (2018) (27)
Mount Sinai's Center for Stress, Resilience and Personal Growth as a model for responding to the impact of COVID-19 on health care workers (2020) (27)
The emergence of ketamine as a novel treatment for posttraumatic stress disorder. (2020) (26)
Rapid synthesis of F-18 and H-2 dual-labeled altanserin, a metabolically resistant PET ligand for 5-HT2a receptors (1999) (26)
Consistency of atypical antipsychotic superiority to placebo in recent clinical trials (2001) (26)
Predictors of differential response to clozapine and haloperidol (1998) (26)
The psychobiology of resilience and vulnerability to anxiety disorders: implications for prevention and treatment (2003) (26)
Assessment of alpha 2 adrenergic autoreceptor function in humans: effects of oral yohimbine. (1982) (26)
Twenty-Four-Hour Urine Cortisol in Combat Veterans with PTSD and Comorbid Borderline Personality Disorder (2003) (26)
“Difficult-to-treat depression” (2003) (26)
Current perspectives on the pathophysiology of schizophrenia, depression, and anxiety disorders. (2001) (25)
Diseases of the mind and brain: depression: a disease of the mind, brain, and body. (2002) (25)
Characteristics of Autonomous Depression (1980) (25)
Effects of light on low nocturnal bilirubin in winter depression: a preliminary report (2002) (25)
Comparison of three high affinity SPECT radiotracers for the dopamine D2 receptor. (1994) (25)
Behavioral, biochemical, and blood pressure responses to alprazolam in healthy subjects: Interactions with Yohimbine (2004) (25)
The effect of ketamine on pre-pulse inhibition and attention (1995) (24)
Continuous intravenous infusion of iodine-123-IBZM for SPECT determination of human brain dopamine receptor occupancy by antipsychotic agent RWJ-37796. (1996) (24)
Ritanserin antagonism of m-chlorophenylpiperazine effects in neuroleptic-free schizophrenics patients: support for serotonin-2 receptor modulation of schizophrenia symptoms (2002) (24)
Leadership and Resilience (2017) (24)
Neurobiology of posttraumatic stress disorder. (1992) (24)
Quantitation of benzodiazepine receptor binding with PET [11C]iomazenil and SPECT [123I]iomazenil: preliminary results of a direct comparison in healthy human subjects (1999) (23)
Children, stress, and sensitization: an integration of basic and clinical research on emotion? (2002) (23)
Manic symptoms following addition of lithium to antidepressant treatment. (1984) (23)
Ciliary neurotrophic factor null allele frequencies in schizophrenia, affective disorders, and Alzheimer's disease. (1997) (23)
Retrospective cohort study of clinical characteristics of 2199 hospitalised patients with COVID-19 in New York City (2020) (23)
Stimulation of reactive oxygen species production by an antidepressant visible light source (2001) (22)
Major depression and panic disorder: diagnostic and neurobiological relationships. (1986) (22)
Equilibrium modeling of 5-HT(2A) receptors with [18F]deuteroaltanserin and PET: feasibility of a constant infusion paradigm. (2000) (22)
The Serotonin Transporter and Emotionality: Risk, Resilience, and New Therapeutic Opportunities (2011) (22)
Kinetic and equilibrium analyses of [(123)I]epidepride binding to striatal and extrastriatal dopamine D(2) receptors. (1999) (22)
The use of placebos in randomized clinical trials of mood disorders: well justified, but improvements in design are indicated (2000) (22)
The MCP-4/MCP-1 ratio in plasma is a candidate circadian biomarker for chronic post-traumatic stress disorder (2017) (21)
Effects of trazodone treatment on serotonergic function in depressed patients (1988) (21)
Plasma NPY concentrations during tryptophan and sham depletion in medication-free patients with remitted depression. (2008) (21)
A Resilience-Building App to Support the Mental Health of Health Care Workers in the COVID-19 Era: Design Process, Distribution, and Evaluation (2021) (21)
Diagnosing bipolar disorder in trauma exposed primary care patients. (2007) (21)
Effects of age and alcoholism on the prevalence of panic disorder (1992) (21)
Anxiety disorders: noradrenergic neurotransmission. (2005) (21)
Family history in delusional depression. (1984) (21)
Does the cholecystokinin antagonist proglumide possess antipsychotic activity? (1986) (21)
Serum triiodothyronine elevation in Israeli combat veterans with posttraumatic stress disorder: A cross-cultural study (1996) (21)
The effect of long-term imipramine treatment on carbon dioxide-induced anxiety in panic disorder patients. (1990) (21)
Fenfluramine augmentation in tricyclic-refractory depression. (1990) (20)
Rapid detoxification from opioid dependence. (1989) (20)
A New Rapid-Acting Antidepressant (2020) (20)
Developing cognitive-emotional training exercises as interventions for mood and anxiety disorders (2015) (20)
Seasonal Variation in Neuroendocrine and Mood Responses to IV L-Tryptophan in Depressed Patients and Healthy Subjects (1996) (20)
The effect of IV l-tryptophan on prolactin, growth hormone, and mood in healthy subjects (2004) (20)
Unmedicated, remitted patients with major depression have decreased serum immunoglobulin A (2012) (19)
Hippocampus, VI. Depression and the Hippocampus. (2005) (19)
Antidepressant Ef fi cacy of Ketamine in Treatment-Resistant Major Depression : A Two-Site Randomized Controlled Trial (2013) (19)
Lithium and desipramine versus desipramine alone in the treatment of severe major depression: a preliminary study (1998) (19)
The Impact of the Homecoming Reception on the Development of Posttraumatic Stress Disorder: The West Haven Homecoming Stress Scale (WHHSS) (1997) (19)
Responses to Trauma: Normal Reactions or Pathological Symptoms (2004) (18)
A case of alprazolam, but not lorazepam, inducing manic symptoms. (1987) (18)
Effects of yohimbine in obsessive compulsive disorder (2004) (18)
Overview of psychiatric disorders and the role of newer antidepressants. (2002) (18)
Review : The Neurobiological Basis of Anxiety and Fear: Circuits, Mechanisms, and Neurochemical Interactions (Part I (1998) (18)
The biological basis of panic disorder. Discussion (1996) (18)
Association study of DTNBP1 with schizophrenia in a US sample (2009) (17)
COVID-19 Pandemic Support Programs for Healthcare Workers and Implications for Occupational Mental Health: A Narrative Review (2021) (17)
The impact of time spent on the electronic health record after work and of clerical work on burnout among clinical faculty (2021) (17)
Intravenous ketamine for treatment-resistant major depressive disorder (2008) (17)
Adaptation to Stress and Psychobiological Mechanisms of Resilience (2008) (17)
FALSE-POSITIVE DIAGNOSIS WITH PRIMARY-AFFECTIVE-DISORDER CRITERIA (1978) (17)
Effect of Methadone Dose on Cocaine Abuse in a Methadone Program (1992) (17)
Effects of alprazolam and clonidine on carbon dioxide-induced increases in anxiety ratings in healthy human subjects. (1989) (16)
Methyl 3 beta-(4-[125I]iodophenyl)tropane-2 beta-carboxylate in vitro binding to dopamine and serotonin transporters under "physiological" conditions. (1994) (16)
Adaptation to Stress and Psychobiological Mechanisms of Resilience (2008) (16)
Dose-response relationship for oral idazoxan effects in healthy human subjects: comparison with oral yohimbine (2005) (16)
Iatrogenic opiate addiction: successful detoxification with clonidine. (1980) (16)
Lymphocyte β-adrenergic receptor binding in panic disorder (2004) (15)
Alpha 2-adrenergic and opiate receptor blockade. Synergistic effects on anxiety in healthy subjects. (1986) (15)
Multiple sclerosis presenting as major depression: a diagnosis suggested by MRI scan but not CT scan. (1988) (15)
Sub-millimeter variation in human locus coeruleus is associated with dimensional measures of psychopathology: An in vivo ultra-high field 7-Tesla MRI study (2020) (15)
A complete remote-control system for reliable preparation of [18F]altanserin. (1999) (15)
Lymphocyte beta-adrenergic receptor binding in panic disorder. (1988) (15)
6 Keys to Resilience for PTSD and Everyday Stress: Teach Patients Protective Attitudes and Behaviors (2007) (15)
Serotonin transporter genotype and depressive phenotype determination by discriminant analysis of glucose metabolism under acute tryptophan depletion (2008) (14)
A Randomized Controlled Trial of Intranasal Neuropeptide Y in Patients With Major Depressive Disorder (2020) (14)
Resilience and Mental Health: Neurobiology of resilience (2011) (14)
Neurobiology of Anxiety Disorders (2009) (14)
Prolonged cocaine psychosis implies underlying major psychopathology. (1991) (14)
Baclofen-assisted detoxification from opiates. A pilot study. (1992) (13)
Factors Associated With Longitudinal Psychological and Physiological Stress in Health Care Workers During the COVID-19 Pandemic: Observational Study Using Apple Watch Data (2020) (13)
Comparison of outcome between homogeneous and heterogeneous treatment environments in combat-related posttraumatic stress disorder. (1999) (13)
CALCYON gene variation, schizophrenia, and cocaine dependence (2004) (13)
Resilience: The role of accurate appraisal, thresholds, and socioenvironmental factors. (2015) (13)
Effects of the CCKB antagonist CI-988 on responses to mCPP in generalized anxiety disorder (1999) (13)
A prospective cohort study of the psychological consequences of the COVID-19 pandemic on frontline healthcare workers in New York City (2022) (13)
Dr. Bremner and Colleagues Reply (1996) (13)
Foundation for the NIMH strategic plan for mood disorders research (2002) (13)
Next generation antidepressants (2013) (13)
The clinical utility of family history for the diagnosis of melancholia. (1984) (13)
CSF TRYPTOPHAN, 5-HIAA AND HVA IN 132 PSYCHIATRIC PATIENTS CATEGORIZED BY DIAGNOSIS AND CLINICAL STATE (1981) (13)
Plasma neuropeptide Y (NPY) increases in humans in response to the alpha 2 antagonist yohimbine. (1998) (13)
Erratum: VNS therapy in treatment-resistant depression: Clinical evidence and putative neurobiological mechanisms (Neuropsychopharmacology (2006) 31 (1345-1355) DOI: 10.1038/sj.npp.1301082) (2006) (13)
Elevated central levels of interleukin-2 in drug-free schizophrenic patients (1991) (13)
Unmet needs in the diagnosis and treatment of mood disorders in later life (2002) (12)
Cognitive and behavioral components of resilience to stress (2020) (12)
310. Transcranial magnetic stimulation and hallucinated ‘voices’ (1998) (12)
Cellular plasticity and resilience and the pathophysiology of severe mood disorders (2004) (12)
Recent Developments in the Neurobiology of Dissociation (1996) (12)
304. Cortical GABA reduced in unipolar but not bipolar depression (2000) (12)
SSRIs in the treatment of panic disorder (1998) (12)
Corticotropin-Releasing Factor Type 1 Receptor Antagonists for Stress-Related Disorders: Time to Call It Quits? (2017) (12)
Clinical Characteristics and Personality Patterns (2015) (12)
Pharmacotherapy for recently evacuated military casualties. (1993) (12)
Reserpine augmentation of desipramine in refractory depression: clinical and neurobiological effects (2004) (12)
The National Bioethics Advisory Commission report: the response of the psychiatric research community is critical to restoring public trust. (1999) (11)
Ready for Anything (2013) (11)
Transdiagnostic Psychiatric Symptoms, Burnout, and Functioning in Frontline Health Care Workers Responding to the COVID-19 Pandemic: A Symptomics Analysis. (2021) (11)
A Call to Protect the Health Care Workers Fighting COVID-19 in the United States. (2020) (11)
Clozapine's cost effectiveness. (1995) (10)
Receptor sensitivity and the mechanism of action of antidepressant treatment: implications for the etiology and therapy of depression (1982) (10)
Reduced Cortical g -Aminobutyric Acid Levels in Depressed Patients Determined by Proton Magnetic Resonance Spectroscopy (1999) (10)
Longitudinal Physiological Data from a Wearable Device Identifies SARS-CoV-2 Infection and Symptoms and Predicts COVID-19 Diagnosis (2020) (10)
Models of antidepressant action. (1999) (10)
Modulating ketamine-induced thought disorder with lorazepam and haloperidol in humans (1995) (10)
It Is Time to Take a Stand for Medical Research and Against Terrorism Targeting Medical Scientists (2008) (9)
Pharmacokinetics of the three radioiodinated dopamine D2 receptor ligands [123I]IBF, [123I]epidepride and [123I]2'-ISP in nonhuman primates. (1994) (9)
Dose-related effects of the NMDA antagonist, ketamine, in healthy humans (1993) (9)
Fighting the Psychological War on Terrorism (2004) (9)
Toward evidence-based early interventions for acutely traumatized adults and children (2003) (9)
Serotonin Function in Panic and Generalized Anxiety Disorders (1990) (9)
Effect of psychiatric intervention on use of antihemophilic factor concentrate. (1980) (9)
Neuroimaging correlates and predictors of response to repeated-dose intravenous ketamine in PTSD: preliminary evidence (2019) (9)
Effects of trazodone treatment on alpha-2 adrenoceptor function in depressed patients (2004) (9)
A randomized, controlled pilot trial of the Emotional Faces Memory Task: a digital therapeutic for depression (2018) (9)
Characterization of the dopamine transporter in nonhuman primate brain: homogenate binding, whole body imaging, and ex vivo autoradiography using [125I] and [123I]IPCIT. (1995) (8)
Population admixture modulates risk for alcohol dependence (2009) (8)
Mazindol and cocaine addiction in schizophrenia (1992) (8)
Integration of in vivo and in vitro approaches to characterize the toxicity of Antalarmin, a corticotropin-releasing hormone receptor antagonist. (2008) (8)
Serum triiodothyronine elevation with posttraumatic stress disorder: a cross-cultural study. (1996) (8)
Initial Clinical Evidence of Genetic Contributions to Posttraumatic Stress Disorder (1998) (8)
Serotonin Transporter Binding in Bipolar Disorder Assessed using ( 11 C)DASB and Positron (2006) (8)
Serotonergic function during lithium augmentation of refractory depression (2005) (8)
Platelet alpha-2-receptor binding and adenylate cyclase activity in panic disorder (2004) (8)
Altered cerebral benzodiazepine receptor binding in post-traumatic stress disorder (2018) (8)
Interrater reliability levels of multiple clinical examiners in the evaluation of a schizophrenic patient: quality of life, level of functioning, and neuropsychological symptomatology. (1999) (8)
The Emerging Neurobiology of Dissociative States (2000) (8)
A review of behavioral and pharmacologic studies relevant to the application of CO2 as a human subject model of anxiety. (1988) (8)
Whole blood transcriptional signatures associated with rapid antidepressant response to ketamine in patients with treatment resistant depression (2022) (8)
Fluvoxamine as an antiobsessional agent. (1989) (8)
Altered gene expression and PTSD symptom dimensions in World Trade Center responders (2021) (8)
Treatment of Depression The Science of Resilience: Implications for the Prevention and (2012) (8)
Psychological Resilience in Frontline Health Care Workers During the Acute Phase of the COVID-19 Pandemic in New York City. (2020) (8)
Hipnóticos y sedantes (2006) (7)
NEW REQUIREMENTS FOR MANUSCRIPTS SUBMITTED TO BIOLOGICAL PSYCHIATRY : INFORMED CONSENT AND PROTECTION OF SUBJECTS (1999) (7)
The Neurobiology of Aggression (2011) (7)
Seminal emission induced by tricyclic antidepressant. (1984) (7)
Erratum to: Risk Factors for the Development of Psychopathology Following Trauma (2015) (7)
Psychological Consequences Among Residents and Fellows During the COVID-19 Pandemic in New York City: Implications for Targeted Interventions (2021) (7)
Marijuana (cannabis) use is anecdotally said to precipitate anxiety symptoms in patients with panic disorder. Is there any research evidence to support this? Also, can marijuana use precipitate or expose paranoia in patients with an underlying bipolar disorder? (1990) (7)
NEUROENDOCRINE CHALLENGE TESTS IN AFFECTIVE DISORDERS: IMPLICATIONS FOR FUTURE PATHOPHYSIOLOGICAL INVESTIGATIONS (1991) (7)
Effects of serotonergic agonists on neuroendocrine responses of rhesus monkeys and patients with depression and anxiety disorders. (1989) (7)
A developmental and neurobiological approach to early trauma research. (2002) (7)
Neurodevelopmental Mechanisms in Psychopathology: The Neurobiology of Child and Adolescent Depression: Current Knowledge and Future Directions (2003) (6)
Differentiating nmda dysregulation in schizophrenia and alcoholism using ketamine (1995) (6)
Searching for Rational Anti–N-methyl-D-aspartate Treatment forDepression—Reply (2007) (6)
Neuropathology of Stress: Prospects and Caveats (2004) (6)
SEROTONIN AND SCHIZOPHRENIA : A REVIEW (1996) (6)
Active and inactive enantiomers of 2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane: comparison using homogenate binding and single photon emission computed tomographic imaging. (1994) (6)
MCPP effects in schizophrenic patients before and after typical and atypical neuroleptic treatment (1991) (6)
SPECT imaging of synaptic dopamine release in drug free schizophrenic patients: An experimental validation of the dopamine hypothesis of schizophrenia (1996) (6)
Emotion Regulation: An Affective Neuroscience Approach (2003) (6)
The role of noradrenergic function in human anxiety and depression (1994) (6)
Tryptophan depletion paradigm: Implications for schizophrenia (1994) (6)
Principles of the Pharmacotherapy of Depression (2011) (6)
Pathological gambling: a current perspective. (2001) (6)
The genetic interacting landscape of 63 candidate genes in Major Depressive Disorder: an explorative study (2014) (6)
beta-Endorphin/beta-lipotropin immunoreactivity in endogenous depression. Effect of dexamethasone. (1986) (6)
Benzodiazepine Receptor Antagonists (1997) (6)
Increasing public trust and confidence in psychiatric research. (1999) (6)
Abnormalities in Catecholamines and the Pathophysiology of Bipolar Disorder (2007) (5)
Desipramine-yohimbine combination treatment of refractory depression. Implications for the ??-adrenergic receptor hypothesis of antidepressant action (1987) (5)
Comparison of [123I]ß-CIT and [123I]IPCIT as single-photon emission tomography radiotracers for the dopamine transporter in nonhuman primates (2005) (5)
Comprar Neurobiology of Mental Illness | Dennis Charney | 9780199798261 | Oxford University Press (2011) (5)
The neural response to emotional expressions in generalized social phobia (GSP) and generalized anxiety disorder (GAD): Evidence for separate disorders (2007) (5)
State-of-science review: E7: The neural basis of resilience (2008) (5)
Neuroendocrine Effects of Serotonin Agonists in Rhesus Monkeys, Healthy Humans and Patients with Depression or Anxiety Disorders: Effects of Antidepressant Treatment (1990) (5)
Kinetic modeling of benzodiazepine receptor binding with PET and high specific activity [11C]Iomazenil in healthy human subjects (2000) (5)
International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators (2022) (5)
Sequence of drug administration in lithium augmentation: a case study. (1988) (5)
Monoaminergic Transmitter Systems (2003) (5)
Behavioral effects of acute tryptophan depletion in depressed patients (1989) (5)
Resilience for Frontline Health Care Workers: Evidence-Based Recommendations (2021) (5)
Polygenic regulation of PTSD severity and outcomes among World Trade Center responders (2020) (5)
Toward Precision Medicine in Psychiatry (2013) (5)
Bipolar disorder: can studies of natural history help us define clinically and neurobiologically relevant subtypes? (2000) (5)
97. Serotonin function and vulnerability to depression (1996) (4)
Human biodistribution and dosimetry of the SPECT D2 dopamine receptor radioligand [123I]IBF. (1996) (4)
Serotonin function and depression (1991) (4)
Resilience and Mental Health: Preface (2011) (4)
Differenital Behavioral and Neural Consequences of Serotonin and Catecholamine Deficiency in Depression: an Experimental Study (2015) (4)
Seasons on the Mind (1998) (4)
SPECTImagingof StriatalDopamineRelease after Amphetamine Challenge (1995) (4)
1. ECT Effects on Cortical GABA Levels as Determined by 1H-MRS (1999) (4)
Fluvoxamine for obsessive-compulsive disorder. (1989) (4)
The role of norepinephrine in the treatment of depression (1999) (3)
Use of yohimbine to counteract nortriptyline-induced orthostatic hypotension. (1989) (3)
Pre-pulse inhibition of the acoustic startle response and measures of attention in schizophrenic subjects (1993) (3)
Spect imaging of the benzodiazepine receptor in schizophrenics and healthy subjects (1995) (3)
I.V. glycine/d-cycloserine to facilitate NMDA function in humans (1994) (3)
The course of major depressive disorder (2002) (3)
Neuropsychiatric Consequences of COVID-19 Pandemic: A Synthetic Review from a Global Perspective (2022) (3)
DSM-5 Overview and Goals (2013) (3)
Ketamine as a prophylactic resilience-enhancing agent (2022) (3)
Reply to: Dose- and Exposure-Response to Ketamine in Depression (2011) (3)
208. Increased striatal dopamine release in drug free schizophrenic subjects (1996) (3)
Resilience and Vulnerability to Trauma (2007) (3)
529 A randomized, double-blind trial of the efficacy and cost-effectiveness of clozapine (1997) (3)
The Neurobiology of Mood Disorders (2002) (3)
A prospective study of transdiagnostic psychiatric symptoms associated with burnout and functional difficulties in COVID-19 frontline healthcare workers (2022) (3)
Update on Biological Psychiatry (2004) (3)
Role of nitric oxide signaling in the antidepressant mechanism of action of ketamine: A randomized controlled trial (2021) (2)
Resilience: Social support (2012) (2)
Attenuation of ketamine effects in healthy humans by lamotrigine, a drug that reduces glutamate release (2000) (2)
NORADRENERGIC DYSFUNCTION IN PANIC ANXIETY: ETIOLOGY AND TREATMENT STUDIES (1984) (2)
No effect of light on basal glucagon levels in winter seasonal depressives and comparison subjects (2000) (2)
Applications of the pharmacologic challenge strategy in panic disorders research (1988) (2)
A randomized pilot study of the prophylactic effect of ketamine on laboratory-induced stress in healthy adults (2022) (2)
Dietary tryptophan restriction produces an upregulation of the neuroendocrine response to infused tryptophan in healthy human subjects (1987) (2)
Anxiety and depression: leading edge of therapy. (2008) (2)
Relationship of Panic Disorder to Posttraumatic Stress Disorder-Reply (1995) (2)
A51 The clinical and economic impact of clozapine treatment of refractory schizophrenia (1993) (2)
The Psychiatric Burden on Medical Students in New York City Entering Clinical Clerkships During the COVID-19 Pandemic (2021) (2)
Soft signs, attention, and startle in schizophrenia (1994) (2)
507 In vivo evaluation of dopamine synaptic funcflon in untreated schizophrenic patients (1997) (2)
Textbook of Disaster Psychiatry: Neurobiology of disaster exposure: fear, anxiety, trauma, and resilience (2007) (2)
The Impact of Early Life Trauma on Health and Disease: Neurobiological factors underlying psychosocial moderators of childhood stress and trauma (2010) (2)
Regional brain uptake and pharmacokinetics of [123I]N-omega-fluoroalkyl-2 beta-carboxy-3 beta-(4-iodophenyl)nortropane esters in baboons. (1995) (2)
The Neurobiology of Personality Disorders: The Shift to DSM-5 (2013) (2)
Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response (2013) (2)
AMPT Effects on Cue-Induced Craving for Cocaine (1996) (2)
D-amphetamine displacement of [123I]IBF equilibrium binding in primates: A new paradigm to investigate D-amphetamine induced dopamine release. (1993) (2)
Preliminary communication Differential performance on tasks of affective processing and decision-making in patients with Panic Disorder and Panic Disorder with comorbid Major Depressive Disorder (2006) (2)
Resilience: What is resilience? (2012) (2)
Sleep architecture in psychotropic-induced somnambulism. (1979) (2)
Use of Physiological Data From a Wearable Device to Identify SARS-CoV-2 Infection and Symptoms and Predict COVID-19 Diagnosis: Observational Study (Preprint) (2020) (1)
Noradrenergic mechanisms in the pathogenesis and treatment of panic disorder (1990) (1)
Comprar Neurobiology of Mental Illness | Benjamin S. Bunney | 9780195325331 | Oxford University Press (2008) (1)
The Effects of Tryptophan Depletion in Depression (1993) (1)
The neuroanatomy of mood disorders. Introduction. (2002) (1)
322. Transcranial magnetic stimulation in treatment-refractory depression (1998) (1)
Attentional threat avoidance during trauma exposure may predict PTSD: (717552011-006) (2013) (1)
Effects of the CCK(B) antagonist CI-988 on responses to mCPP in generalized anxiety disorder. (1999) (1)
Urinary MHPG and Response to Amitriptyline-Reply (1983) (1)
171. A Randomized Controlled Dose-Ranging Study of Intranasal Administration of Neuropeptide Y in Patients with Posttraumatic Stress Disorder (2017) (1)
Lithium Treatment Effect on Serotonin Function-Reply (1990) (1)
Muscarinic cholinergic2 receptor binding in bipolar disorder: Relation to saliency of affective-words (2005) (1)
Research on Major Depression (2017) (1)
Antipsychotic Agents (Neuroleptics): The effect of neuroleptic discontinuation on psychopathology, involuntary movements, and biochemical measures in patients with persistent tardive dyskinesia (1989) (1)
Developments in the first year of a resilience-focused program for health care workers (2021) (1)
218. HPA axis regulation in premenopausal women with PTSD (2000) (1)
An assessment of the catecholamine hypothesis of bipolar disorder (2016) (1)
617 Dose-related ethanol effects in schizophrenic patients (1997) (1)
Abnormal noradrenergic function in panic disorder and PTSD (1994) (1)
Visual Impairment and Patterns of Winter Seasonal Depression: Seeing the Light? (2001) (1)
Mode of action of antidepressants (1993) (1)
Initial Evidence for Brain Plasticity Following a Digital Therapeutic Intervention for Depression (2019) (1)
Ketamine as a Rapid Treatment for Post-Traumatic Stress Disorder (2011) (1)
Comment by Dr. Kaufman et al., at the invitation of the Editor (1999) (1)
Monoamine and neuropeptide-related function: prospects for novel therapeutics of depression (2002) (1)
P310. Effect of a Sub-Anesthetic Infusion of Ketamine on Laboratory-Induced Stress in Healthy Volunteers: A Proof-Of-Concept Translational Study (2022) (1)
Do Dual-Action Neurotransmitter Agents Offer an Advantage in Psychiatric Treatment? (2001) (1)
Molecular neurobiology for the clinician (2003) (1)
The National Center for Post-Traumatic Stress Disorder (1999) (1)
Spect imaging of the benzodiazepine receptor in humans using [123I]iomazenil (1993) (1)
401. One Hertz rTMS of left temporoparietal cortex in schizophrenic patients reporting auditory hallucinations (2000) (1)
Risk of Tryptophan Depletion Following Amino Acid Supplementation-Reply (1993) (1)
The Infirmities of Psychiatric Diagnosis (2013) (1)
New initiatives in Biological Psychiatry (2003) (1)
Correction: Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression (2019) (1)
Update: what’s new in Biological Psychiatry (2001) (1)
The Neurobiology of Social Attachment (2013) (1)
Pharmacotherapy of Anxiety Disorders (2011) (1)
Posttraumatic Stress Disorder: Neurobiology (2009) (1)
The Neurobiology of Sleep (2011) (1)
Ptsd R Esearch Quarterly Animal Models for the Neuro Biology of Trauma (1)
Follow-up Study of Patients With Panic Disorder-Reply (1991) (0)
Ketamine for treatment-resistant depression: Subjective effects and impact on plasma brain-derived neurotrophic factor (2014) (0)
Adrenergic Receptor Sensitivity and the Mechanism of Action of Antidepressant Therapy The Effect of Longâ€”TermAmitriptyline Treatment (2006) (0)
Resilience: The practice of resilience (2012) (0)
RECENT AND RELEVANT (2009) (0)
Drug Repositioning Opportunities in Psychiatry (2017) (0)
Biological correlates of neurosis (1994) (0)
CHAPTER 9:Neurocircuitry of Anxiety Disorders: Focus on Panic Disorder and Post-traumatic Stress Disorder (2012) (0)
Neurobiology and dreams: further queries. (1978) (0)
Deficits in short-term memory in adult survivors abuse of childhood (2003) (0)
Abstracts for 2006 (2006) (0)
Neurobiological Mechanisms of Panic Anxiety: Review of the Behavioral, Biochemical, and Cardiovascular Effects of Three Panicogenic Stimuli (1989) (0)
268. Simultaneous catecholamine and indoleamine depletion in unmedicated depressed subjects (2000) (0)
Introduction/Current Issues in Attention Deficit Disorder (1998) (0)
mCPP in generalized anxiety disorder (1999) (0)
Peer and Family Bonds in Urban Adolescent Survivors of Childhood Trauma (2020) (0)
Biological psychiatry - A journal progress report: Editorial (1998) (0)
618 Evaluation of lorazepam blockade of M-chlorophenylpiperazine (MCPP) effects in schizophrenia (1997) (0)
Association of pessimism with cardiovascular events and all-cause mortality. (2022) (0)
RESPONSES TO MCPP STIMULATION IN DEPRESSED PATIENTS. AUTHORS' REPLY (1995) (0)
Worldview of Psychiatry: Neurodegeneration in Stress and Anxiety Disorders: Mechanisms and Implications (2004) (0)
Machine Learning to Predict Mortality and Critical Events in a Cohort of Patients With COVID-19 in New York City: Model Development and Validation (Preprint) (2020) (0)
Neurobiology and Treatment of Depression (2007) (0)
Current thinking on treatment‐refractory depression (1997) (0)
Childhood trauma and comorbid mood and anxiety disorders in adult patients with post-traumatic stress disorder (2012) (0)
Genetic Contributions to Posttraumatic Stress Disorder (2013) (0)
Brain Fitness: Challenge Your Mind and Heart (2018) (0)
Resilience: Religion and spirituality (2012) (0)
The Peace of Mind Prescription: An Authoritative Guide to Finding the Most Effective Treatment for Anxiety and Depression (2004) (0)
Therapeutic profile of atypical antipsychotic drugs (1991) (0)
Commencement Address, 2013 (2013) (0)
State of the School Address, 2010 (2010) (0)
24. Quantification of cortical GABA levels in neuropsychiatric patients (1998) (0)
Neural Circuitry Mechanisms of Response to Ketamine in PTSD: Preliminary Findings (2022) (0)
ANXIETY AND STRESS DISORDER (2002) (0)
Building Resilience and Well-Being in Health Care Workers in the COVID-19 Era: Lessons Learned and Next Steps-Reply to Modesto-Lowe et al. (2021) (0)
Journals for 2006 (2006) (0)
Forthcoming papers (1990) (0)
Resilience: Cognitive and emotional flexibility (2012) (0)
Resilience: Brain fitness (2012) (0)
REGIONAL CEREBRAL BLOOD FLOW CHANGES IN PATIENTS WITH PANIC DISORDER (1989) (0)
Resilience: Facing fear (2012) (0)
Functional Magnetic Resonance Imaging Study of eliberate Emotion Regulation in Resilience and osttraumatic Stress Disorder (0)
Experimental therapeutics and biological psychiatry (2005) (0)
Clozapine and hospitalization. (1999) (0)
231. Neuroendocrine and psychobiological responses to uncontrollable stress (2000) (0)
Resilience: Further Information about Posttraumatic Stress Disorder (2012) (0)
The Antidepressant Effects of Ketamine are Not Primarily Mediated by Nitric Oxide (2020) (0)
Role Models: Providing the Road Map (2018) (0)
A43 Collection of health care cost data in a VA health services study (CSHS#17) (1996) (0)
68. Brain spect imaging in Parkinson's disease associated with depression (1998) (0)
S.20.01 Adrenal & CSF neurosteroids as mediators of HPA axis upregulation and symptom production in premenopausal women with PTSD (2003) (0)
Contents of the Journal of Nervous and Mental Disease (1993) (0)
The Course of Panic Attacks and Agoraphobia-Reply (1988) (0)
Optimism: Belief in a Brighter Future (2018) (0)
Treatments for Depression (2013) (0)
P.245 Intranasal administration of neuropeptide Y; development of a novel treatment for major depressive disorder (2020) (0)
John H. KrystalLaurence P. KarperAlexandre Bennett (1998) (0)
T129. Brain Connectivity Changes Associated With a Cognitive-Emotional Training Intervention for Depression (2018) (0)
in Endogenous Depression Effect of Dexamethasone (2017) (0)
White Coat Address, 2014 (2010) (0)
Clinical Severity, Personality Characteristics and Maternal Attitudes in Hemophiliac Children (1977) (0)
A Heartfelt Thank You (2006) (0)
Potentiation of the euphoric effects of ketamine in humans by pretreatment with lamotrigine Support for glutamatergic inhibition of the rewarding properties of NMDA antagonists (2000) (0)
Commentary on "Brain Environment Interactions: Stress, Posttraumatic Stress Disorder, and the Need for a Postmortem Brain Collection" Neuropathology of Stress: Prospects and Caveats (2004) (0)
326. GABA-serotonin interactions in healthy subjects: Implications for psychosis (1996) (0)
Resilience: Role models (2012) (0)
Utilization of deuterium isotope effect to enhance specific brain uptake of [18F]altanserin. A 5-HT(2A) radiotracer for PET (1999) (0)
Serotonin syndrome. (1992) (0)
The Neurobiology of Child and Adolescent Current Knowledge and Future Directions (2005) (0)
Jack Peter Green, 1925–2007 (2007) (0)
Religion and Spirituality: Drawing on Faith (2018) (0)
Neural correlates of catecholaminergic dysfunction as a trait abnormality in major depression (2008) (0)
Resilience: Moral compass, ethics, and altruism (2012) (0)
Moral Compass, Ethics, and Altruism: Doing What Is Right (2018) (0)
Our rapid publication policy (2000) (0)
Resilience: Meaning, purpose, and growth (2012) (0)
459. Psycho-biological indices of special operations selection (2000) (0)
Comparative Behavioral and Neural Effects of Tryptophan and Catecholamine Depletion in Remitted Depression (2014) (0)
2013 Daniel H. Efron Research Award (2012) (0)
Personality Characteristics of Adult Hemophiliacs (1977) (0)
Dr. Leibenluft and Colleagues Reply (2004) (0)
West Haven Homecoming Stress Scale (2017) (0)
he Case for Shifting Borderline Personality isorder to Axis I (2008) (0)
The Role of Estrogen on Regulation of Mood in Perimenopausal Women (1998) (0)
Maintaining a Steady Course One of the “Hottest Journals of the Millennium…” (2005) (0)
Serotonin transporter binding in major depressive disorder and bipolar disorder assessed using [11C]DASB and positron emission tomography (2006) (0)
Iodine-123-Whole-Body Biodistribution , Radiation Absorbed Dose and Brain SPECT Imaging with (2006) (0)
Personality Characteristics of Hemophiliac Children (1977) (0)
Comparison of Methods for Quantitative Measurement of Striatal and Extrastriatal Dopamine D2/3 Receptors with [123I]Epidepride (1998) (0)
SEROTONIN SPECIFIC DRUGS FOR THE TREATMENT OF AFFECTIVE AND ANXIETY DISORDERS (1992) (0)
Ketamine effects reduced by lorazepam in healthy humans (1993) (0)
Training: Physical Fitness and Strengthening (2018) (0)
Alcohol Dependence May Be the Missing Link Between Posttraumatic Stress Disorder and Panic-Reply (1994) (0)
Longitudinal Mental Health Outcomes of Third-year Medical Students Rotating Through the Wards During COVID-19 (2022) (0)
Rapid improvement of delusional depression following drug-induced seizures: case report. (1985) (0)
Feasibility of continuation ketamine for treatment-resistant depression (2008) (0)
Drs. Mathew and Charney Reply (2009) (0)
SELECTED NEUROBIOLOGICAL FACTORS IN STRESS-INDUCED DEPRESSION AND STRESS RESILIENCE Serotonin in Stress-Induced Depression and Stress Resilience (2008) (0)

This paper list is powered by the following services:

Other Resources About Dennis S. Charney

en.wikipedia.org

What Schools Are Affiliated With Dennis S. Charney?

Dennis S. Charney is affiliated with the following schools:

Dennis S. Charney's Academic­Influence.com Rankings

Why Is Dennis S. Charney Influential?

Dennis S. Charney's Published Works

Published Works

Other Resources About Dennis S. Charney

What Schools Are Affiliated With Dennis S. Charney?

Image Attributions

Dennis S. Charney's AcademicInfluence.com Rankings